ABSTRACT
The Journal of Clinical Medicine retracts the article "An Admission-to-Discharge BNP Increase Is a Predictor of Six-Month All-Cause Death in ADHF Patients: Inferences from Multivariate Analysis Including Admission BNP and Various Clinical Measures of Congestion" [...].
ABSTRACT
The Journal of Clinical Medicine retracts the article "Vasopressin Receptor Antagonists for the Correction of Hyponatremia in Chronic Heart Failure: An Underutilized Therapeutic Option in Current Clinical Practice [...].
ABSTRACT
The paper entitled "Network meta-analysis: a new analysis tool of the experimental evidence" by Renato De Vecchis et al., which was published in Minerva Medica 2019 Apr;110(2):173-5, has been retracted by the Publisher due to self-plagiarism. The originally published version of this article is available at https://doi.org/10.23736/S0026-4806.18.05768-3.
ABSTRACT
The paper entitled "Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis" by Renato De Vecchis et al., which was published in Minerva Cardioangiologica 2018 October;66(5):659-70, has been retracted by the Publisher due to plagiarism.
ABSTRACT
The paper entitled "Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials" by Renato De Vecchis et al., which was published in Minerva Cardioangiologica 2017 August;65(4):427-42, has been retracted by the Publisher due to self-plagiarism.
ABSTRACT
The paper entitled "Sacubitril/valsartan improves left ventricular longitudinal deformation in heart failure patients with reduced ejection fraction" by Renato De Vecchis et al., which was published in Minerva Cardioangiologica 2019 December;67(6):456-63, has been retracted by the Publisher due to self-plagiarism.
ABSTRACT
The paper entitled "Antihypertensive effect of sacubitril/valsartan: a meta-analysis" by Renato De Vecchis et al., which was published in Minerva Cardioangiologica 2019 June;67(3):214-22, has been retracted by the Publisher due to self-plagiarism.
ABSTRACT
The paper entitled "Authorship growth and self- citations: a scholarly expedient that demonstrates that the use of the metrics for career decisions generates malpractice and misbehavior?" by Renato De Vecchis et al., which was published in Minerva Cardiology and Angiology 2021 October;69(5):619-20, has been retracted by the Publisher due to self-plagiarism.
ABSTRACT
The paper entitled "Ablation, rate or rhythm control strategies for patients with atrial fibrillation: how do they affect mid-term clinical outcomes?" by Renato De Vecchis et al., which was published in Minerva Cardioangiologica 2019 August;67(4):272-9, has been retracted by the Publisher due to self-plagiarism.
ABSTRACT
The journal retracts the article "Platypnea-Orthodeoxia Syndrome: Multiple Pathophysiological Interpretations of a Clinical Picture Primarily Consisting of Orthostatic Dyspnea" by De Vecchis, R [...].
ABSTRACT
CASE DESCRIPTION: A 64-year-old patient with chronic renal failure and persistent hyperkalaemia not corrected by dialysis, was prescribed sodium polystyrene sulfonate (SPS) at a low dose (30 g/day for 2 days a week during the long interdialytic interval). After 3 months of therapy, the patient developed intense abdominal pain with non-specific colitis identified with a colonoscopy. In addition, the biopsy specimens showed rhomboid SPS crystals in the intestinal mucosa. Fourteen months after discontinuing therapy, the patient again presented with colitis and persistent biopsy finding of SPS crystals. The patient died a few months later due to intestinal infarction. DISCUSSION AND CONCLUSION: SPS is a cation exchange resin used to treat hyperkalaemia resistant to dialysis, but may cause inflammation and ischaemia of the colon. In our patient, a short 3-month course of low-dose SPS therapy (without sorbitol, which is used to counter iatrogenic constipation caused by SPS) induced relapsing colitis, which was followed by massive intestinal infarction a few months later. In light of frequent reports of its enterotoxic effects, SPS should be replaced with the new potassium chelators (patiromer and sodium zirconium cyclosilicate). LEARNING POINTS: Sodium polystyrene sulfonate can cause life-threatening colitis.Alternatives medications should be used for the long-term reduction of potassium levels.
Subject(s)
Benchmarking , Temporomandibular Joint Disorders , Altruism , Humans , Interpersonal Relations , TrustABSTRACT
Anthracyclines are the cornerstone of treatment for many solid and hematological cancers such as breast cancer or lymphoma for the past 50 years. Nevertheless, in a non-negligible proportion of patients, they elicit dilated cardiomyopathy as a side effect, which causes in turn cardiac decompensation. Conversely, for some years, sacubitril/valsartan has been proposed as a new therapeutic paradigm for all varieties of heart failure with reduced left ventricular ejection fraction, due to its balanced enhancement of natriuretic peptides' properties coupled with a blocking effect on the AT1 angiotensin receptors. In this article, two clinical cases are illustrated in which the therapeutic action of sacubitril/valsartan against anthracycline cardiomyopathy would seem to be demonstrated by the improvement of symptoms and echocardiographic parameters. Thus, further studies would be warranted for better evaluating the potential role of sacubitril/valsartan as a novel therapeutic tool against anthracycline cardiotoxicity.
ABSTRACT
The therapy or prevention of atrial fibrillation (AF) is defined as upstream therapy when conducted with the use of drugs, e.g., angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor antagonists, statins, and omega-3 fatty acids, not included in the classes of antiarrhythmic drugs recognized by the Vaughan Williams classification. In our review, we illustrate the rational bases of upstream AF therapy, which encompasses drugs having the property to reduce hemodynamic congestion and cardiac overload, as in the case of ACEIs or angiotensin receptor blockers, as well as drugs able to prevent atrial fibrosis or reduce oxidative stress, such as statins or omega-3 fatty acids, respectively. In this review, randomized controlled trials (RCTs) conducted with the abovementioned drugs are examined. Really, these RCTs have generated mixed results. In the context of the prevention and therapy of AF, our experience is then presented, relating to a patient with heart failure and reduced left ventricular ejection fraction, with a history of relapsing episodes of paroxysmal AF. In this patient, administration of sacubitril/valsartan at appropriate doses allowed recovery of the sinus rhythm. Therefore this case testifies how the upstream therapy of AF might have good results when conducted with sacubitril/valsartan. Thus, RCTs with adequate statistical power are warranted in order to confirm the preliminary encouraging result of our case report, and validate a useful role of sacubitril/valsartan as an upstream therapy of AF.
ABSTRACT
The paper entitled "Effects of a restricted water intake on various clinical and laboratory outcomes in patients with heart failure: a meta-analysis of randomized controlled trials" by Renato De Vecchis et al, which was published online on February 20, 2020, has been withdrawn by the Publisher due to self-plagiarism.
